Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.

Hubalek M, Brantner C, Marth C.

Wien Med Wochenschr. 2010 Apr;160(7-8):167-73. doi: 10.1007/s10354-010-0771-8.

PMID:
20473727
2.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
3.

Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.

Michaud LB, Buzdar AU.

Drugs Aging. 2000 Apr;16(4):261-71. Review.

PMID:
10874521
4.

Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.

Tan SH, Wolff AC.

Clin Breast Cancer. 2007 Feb;7(6):455-64. Review.

PMID:
17386122
5.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD.

J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46.

6.

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.

Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes H, Forbes J, et al.

Ann Oncol. 1994 Oct;5(8):717-24.

PMID:
7826904
7.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004562.

PMID:
18843661
8.

Adjuvant hormonal therapy for premenopausal women with breast cancer.

Emens LA, Davidson NE.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):486S-94S.

9.

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.

Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H; Austrian Breast and Colorectal Cancer Study Group Trial 5.

J Clin Oncol. 2002 Dec 15;20(24):4621-7.

PMID:
12488405
10.
12.
13.

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer.

J Clin Oncol. 2001 Jan 15;19(2):343-53.

PMID:
11208825
14.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
15.

Adjuvant endocrine treatment in premenopausal early breast cancer.

Orlando L, Fedele P, Cinefra M, Sponziello F, Calvani N, Chetrì MC, Rizzo P, D'Amico M, Schiavone P, Portaluri M, Criscuolo M, Burlizzi S, Cinieri S.

Oncology. 2009;77 Suppl 1:9-13. doi: 10.1159/000258490. Epub 2010 Feb 2. Review.

PMID:
20130426
16.

Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).

Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K; TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).

Anticancer Res. 2002 Jul-Aug;22(4):2325-32.

PMID:
12174922
18.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
19.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

20.

Controversies in adjuvant endocrine treatment of premenopausal women.

Goldstein LJ.

Clin Breast Cancer. 2006 Feb;6 Suppl 2:S36-40. Review.

PMID:
16595024
Items per page

Supplemental Content

Write to the Help Desk